BOSTON – November 10, 2020 – CureLab Oncology, a clinical-stage pre-IPO biotech company, has established business development operations in the European Union. CureLab is looking to identify partners in the region to test the efficacy of the company’s DNA-based products against cancers and non-cancerous diseases of chronic inflammation and bring them to the European market.
To lead business operations in the EU, CureLab has appointed Ricarda Cramer, who brings more than 15 years’ experience in the healthcare industry and a deep understanding of the pharmaceutical industry, including in-licensing and out-licensing through local partnerships. The EU office will also spearhead local investor relations and grant applications.
““We’re especially interested in connecting with mid-size companies in Europe to license specific applications, so Ricarda’s experience and connections will be invaluable,” said Dr. Alexander Shneider, founder and CEO of CureLab Oncology. “We’re delighted to welcome her to the CureLab team as we ramp up our 2021 initiatives in the European region.”
Operating out of Frankfurt, Germany, Ms. Cramer will focus CureLab’s licensing efforts on therapies for various cancers, diseases of chronic inflammation such as psoriasis, diabetes, osteoporosis, CNS diseases, and aging.
“I am thrilled to join the CureLab team on its exciting journey to bring life-saving therapies to critically ill oncology patients in Europe, and to find partners that share our passion for immuno-oncological therapies,” said Ricarda Cramer, business development director for CureLab Oncology Europe.
CureLab’s lead product, Elenagen, is a DNA encoding gene called p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (such as chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.
CureLab Oncology Inc. is a clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications.